Investors were underwhelmed by the solid earnings posted by Eton Pharmaceuticals, Inc. (NASDAQ:ETON) recently. We did some digging and actually think they are being unnecessarily pessimistic.
View our latest analysis for Eton Pharmaceuticals
Examining Cashflow Against Eton Pharmaceuticals' Earnings
As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF.
As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.
For the year to September 2023, Eton Pharmaceuticals had an accrual ratio of -2.96. That implies it has very good cash conversion, and that its earnings in the last year actually significantly understate its free cash flow. To wit, it produced free cash flow of US$9.3m during the period, dwarfing its reported profit of US$2.23m. Notably, Eton Pharmaceuticals had negative free cash flow last year, so the US$9.3m it produced this year was a welcome improvement.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Eton Pharmaceuticals' Profit Performance
Happily for shareholders, Eton Pharmaceuticals produced plenty of free cash flow to back up its statutory profit numbers. Based on this observation, we consider it possible that Eton Pharmaceuticals' statutory profit actually understates its earnings potential! And it's also positive that the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So while earnings quality is important, it's equally important to consider the risks facing Eton Pharmaceuticals at this point in time. In terms of investment risks, we've identified 2 warning signs with Eton Pharmaceuticals, and understanding them should be part of your investment process.
This note has only looked at a single factor that sheds light on the nature of Eton Pharmaceuticals' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.